Form 4: Cardiff Oncology Director Receives Stock Option Grant

Director James O. Armitage was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation arrangement.

Summary

• Director James O. Armitage acquired 40,565 stock options in Cardiff Oncology, Inc. (CRDF).
• The options have an exercise price of $1.59 per share.
• The grant was issued on June 11, 2026, with an expiration date of June 11, 2036.
• Following this transaction, the director's total beneficial ownership of derivative securities increased to 228,104.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $1.59 may be subject to market fluctuations relative to the future trading price of CRDF.

Future Outlook

The options vest on June 11, 2027, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and terms are consistent with typical non-employee director compensation packages for small-cap biotechnology firms.
• Vesting schedules of one year are common for annual director equity refreshes in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 11, 2027.

Key Dates

Keywords

Cardiff Oncology, CRDF, Form 4, Insider Trading, Stock Options, Director Compensation